Rank 23 • MedTech & Devices
Cleerly
Leverages AI to analyze coronary CT angiograms, measuring and characterizing plaque to prevent future heart attacks.
Visit website- Signal Score
- 90.7
- Total raised
- $248M
- Stage
- Series C
- Founded
- 2017
- Headquarters
- Denver, United States
- Region
- North America
Their signal
Supported by vast multi-center clinical trials, Cleerly shifts cardiac care from reactive symptom management to proactive, plaque-based prevention strategies.
Signal Score 90.7editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in MedTech & Devices
Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.